Wall Street brokerages expect R1 RCM Inc (NASDAQ:RCM) to report $0.08 earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for R1 RCM’s earnings, with the highest EPS estimate coming in at $0.08 and the lowest estimate coming in at $0.07. R1 RCM posted earnings of $0.01 per share in the same quarter last year, which suggests a positive year over year growth rate of 700%. The business is scheduled to issue its next earnings results on Friday, February 28th.
On average, analysts expect that R1 RCM will report full year earnings of $0.01 per share for the current year, with EPS estimates ranging from $0.00 to $0.01. For the next financial year, analysts forecast that the business will post earnings of $0.51 per share, with EPS estimates ranging from $0.31 to $0.72. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow R1 RCM.
R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Tuesday, November 5th. The healthcare provider reported $0.01 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by ($0.08). R1 RCM had a negative net margin of 0.13% and a positive return on equity of 100.31%. The company had revenue of $301.20 million during the quarter, compared to analyst estimates of $302.85 million. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. R1 RCM’s revenue for the quarter was up 20.3% on a year-over-year basis.
RCM has been the topic of several research reports. BidaskClub upgraded shares of R1 RCM from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Zacks Investment Research cut shares of R1 RCM from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 27th. ValuEngine raised shares of R1 RCM from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Robert W. Baird set a $14.00 target price on shares of R1 RCM and gave the company a “buy” rating in a research report on Thursday, September 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. R1 RCM has a consensus rating of “Buy” and an average target price of $13.40.
Institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in R1 RCM by 38.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,817 shares of the healthcare provider’s stock worth $52,000 after purchasing an additional 1,625 shares during the period. Virtu Financial LLC bought a new stake in R1 RCM during the third quarter worth about $111,000. Aperio Group LLC bought a new stake in R1 RCM during the second quarter worth about $127,000. NumerixS Investment Technologies Inc lifted its position in R1 RCM by 73.3% during the second quarter. NumerixS Investment Technologies Inc now owns 10,400 shares of the healthcare provider’s stock worth $131,000 after purchasing an additional 4,400 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in R1 RCM during the second quarter worth about $139,000. 70.59% of the stock is owned by institutional investors.
Shares of NASDAQ:RCM traded down $0.50 on Monday, hitting $12.39. The company had a trading volume of 1,100,800 shares, compared to its average volume of 1,000,207. R1 RCM has a 1-year low of $7.10 and a 1-year high of $13.19. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -38.72 and a beta of 0.18. The stock has a 50 day moving average price of $11.42 and a 200 day moving average price of $11.59. The company has a current ratio of 0.94, a quick ratio of 0.94 and a debt-to-equity ratio of 29.28.
R1 RCM Company Profile
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.
Recommended Story: Price Target
Get a free copy of the Zacks research report on R1 RCM (RCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for R1 RCM Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for R1 RCM and related companies with MarketBeat.com’s FREE daily email newsletter.
